Respiratory Syncytial Virus Prophylaxis in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2030

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report

Published: August 04, 2025 Report Code: GDHC323PIDR-8M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

The report provides an in-depth assessment of the RSV prophylaxis market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook.

RSV is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) orthopneumovirus belonging to the Pneumoviridae family. The most common clinical scenario for RSV is an upper respiratory tract infection (URTI), which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between two to three months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which on rare occasions can progress to respiratory failure or death. RSV is also an important cause of hospitalizations and deaths in elderly adults.

Across the 8MM, GlobalData expects the RSV prophylaxis market to grow at a compound annual growth rate (CAGR) of 28.6% over the 2020–30 forecast period, reaching $7.2 billion by 2030. In 2020, the RSV prophylaxis market was valued at $582M, with all sales attributable to AstraZeneca/AbbVie's Synagis (palivizumab), a monoclonal antibody (mAb) indicated for use in high-risk infants. The RSV prophylaxis market has undergone significant growth and diversification in the following years owing to the launch of two more mAbs, AstraZeneca/Sanofi's Beyfortus (nirsevimab) and Merck &Co’s Enflonsia (clesrovimab), as well as the first RSV vaccines, GSK’s Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA. Five vaccines in late-stage development will also drive market growth. These are GSK’s GSK-3888550A, AdVaccine’s BARS-13, and Sanofi’s SP-0256, SP-0274, and SP-0125.

Scope

Overview of RSV including etiology, pathophysiology and epidemiology.

Key topics covered include current market landscape, strategic competitor assessment, unmet needs and opportunities, R&D trends, pipeline assessment, and current and future players.

RSV prophylaxis market outlook from 2020-2030, including annual cost of therapy per patient, and total sales revenues per product for each of the 8MM.

Key Highlights

Report deliverables include a Word report and an Excel-based forecast model

Forecast includes the 8 major markets (8MM)

Forecast covers the period 2020-2030

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and identify the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 8MM RSV prophylaxis market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM RSV prophylaxis market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Beijing Advaccine Biotechnology Company
GSK
Sanofi
AbbVie
Sobi
AstraZeneca
Merck & Co
Pfizer
Moderna

List of Contents

List of Tables

List of Figures

1 Respiratory Syncytial Virus Prophylaxis: Executive Summary – Updated July 2025, based on events up to July 2025

1.1 Summary of changes

1.2 RSV prophylaxis market to reach $7.2 billion by 2030

1.3 Unmet needs remain despite influx of novel products

1.4 Prophylactic options to continue to diversify due to strength of late-stage pipeline

1.5 What do physicians think?

2 Introduction – Updated July 2025, based on events up to July 2025

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview – Updated Nov 2024, based on events up to Nov 2024

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology – Updated Aug 2021, based on events up to Aug 2021

4.1 Disease background

4.1.1 Risk factors and comorbidities

4.2 Global and historical trends

4.3 Forecast methodology

4.3.1 Sources

4.3.2 Forecast assumptions and methods

4.4 Epidemiological forecast for RSV prophylactic population (2020–30)

4.4.1 Number of preterm births by gestational age

4.4.2 Preterm infants with CLD

4.4.3 Number of live births with hemodynamically significant heart disease and congenital lung disease

4.4.4 Diagnosed prevalent cases of DMD

4.4.5 Diagnosed prevalent cases of SMA

4.4.6 Number of third-trimester pregnant women

4.4.7 Number of adults living in nursing homes/long-term care institutions

4.5 Discussion

4.5.1 Epidemiological forecast insight

4.5.2 Limitations of the analysis

4.5.3 Strengths of the analysis

5 Disease Management – Updated July 2025, based on events up to July 2025

5.1 Diagnosis

5.2 Prophylaxis

5.3 Treatment

5.4 KOL insights on disease management

6 Current Treatment Options – Updated July 2025, based on events up to July 2025

6.1 Overview

7 Unmet Needs and Opportunity Assessment – Updated July 2025, based on events up to July 2025

7.1 Overview

7.2 Increased diagnostic testing

7.3 Increased research and awareness of long-term sequelae

7.4 Combination vaccines

7.5 Prophylaxis for immunocompromised patients

8 R&D Strategies – Updated July 2025, based on events up to July 2025

8.1 Overview

8.1.1 Leveraging novel vaccine technologies and strategies

8.1.2 Development of prophylactic antibodies with improved dosing and efficacy

8.2 Clinical trial design

8.2.1 Clinical trial design for RSV prophylactics for maternal immunization

8.2.2 Clinical trial design for RSV prophylactics for pediatric immunization

8.2.3 Clinical trial design for RSV prophylactics for adult immunization

9 Pipeline Assessment – Updated July 2025, based on events up to July 2025

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis – Updated July 2025, based on events up to July 2025

10.1 Overview

10.2 Competitive assessment

10.2.1 Pipeline maternal vaccine products

10.2.2 Pipeline vaccine products for adults

11 Current and Future Players – Updated July 2025, based on events up to July 2025

11.1 Overview

11.2 Deal-making trends

12 Market Outlook – Updated July 2025, based on events up to July 2025

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

12.5 Australia

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary Research – KOLs interviewed for this report

13.5 Primary research – prescriber survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Epidemiology Reviewers

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence

About GlobalData

Table

Table 1: Respiratory Syncytial Virus: Key Metrics in the 8MM

Table 2: Risk factors for severe RSV

Table 3: Leading therapies for RSV prophylaxis, 2024

Table 4: Guidelines for RSV Prophylaxis

Table 5: Clinical trial designs for RSV vaccines for maternal immunization

Table 6: Clinical trial designs for RSV prophylactics for pediatric patients

Table 7: Clinical trial designs for RSV prophylactics for adult patients

Table 8: Top 5 deals by value, 2019–24

Table 9: RSV prophylactics market – global drivers and barriers, 2020–30

Table 10: Key events impacting sales for RSV prophylaxis in the US, 2020–30

Table 11: RSV prophylactics market – drivers and barriers in the US, 2020–30

Table 12: Key events impacting sales for RSV prophylaxis in the 5EU, 2020–30

Table 13: RSV prophylactics market – drivers and barriers in the 5EU, 2020–30

Table 14: Key events impacting sales for RSV prophylaxis in Japan, 2020–30

Table 15: RSV prophylactics market – drivers and barriers in Japan, 2020–30

Table 16: Key events impacting sales for RSV prophylaxis in Australia, 2020–30

Table 17: RSV prophylactics market – drivers and barriers in Australia, 2020–30

Table 18: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global (8MM) sales forecast by country for RSV prophylactics in 2020 and 2030

Figure 2: Structure of human RSV virion

Figure 3: RSV life cycle

Figure 4: 8MM, rate of preterm births (per 1,000 live births), 2020–30

Figure 5: 8MM, percentage of adults living in long-term care, ages ≥55 years, 2020–30

Figure 6: 8MM, sources used to forecast the number of preterm births

Figure 7: 8MM, sources used to forecast the number of preterm births with CLD

Figure 8: 8MM, sources used to forecast the number of live births with hemodynamically significant heart disease

Figure 9: 8MM, sources used to forecast the number of live births with congenital lung disease

Figure 10: 8MM, sources used to forecast the diagnosed prevalent cases of DMD

Figure 11: 8MM, sources used to forecast the diagnosed prevalent cases of SMA

Figure 12: 8MM, sources used to forecast the number of third-trimester pregnancies

Figure 13: 8MM, sources used to forecast the number of adults living in long-term care

Figure 14: 8MM, number of preterm births by gestational age, N, 2020

Figure 15: 8MM, number of preterm infants with CLD, N, 0-year, 2020–30

Figure 16: 8MM, number of live births with hemodynamically significant heart disease and congenital lung disease, 2020, 0-year

Figure 17: 8MM, diagnosed prevalent cases of DMD in boys, ages 0–2 years, 2020–30

Figure 18: 8MM, diagnosed prevalent cases of SMA, boys and girls, ages 0–2 years, 2020–30

Figure 19: 8MM, number of third-trimester pregnant women, N, 2020–30

Figure 20: 8MM, number of adults living in care institutions, ages ≥55 years, N, 2020–30

Figure 21: Unmet needs and opportunities in RSV

Figure 22: Overview of the development pipeline in RSV

Figure 23: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for RSV in the 8MM during the forecast period

Figure 24: Competitive assessment of pipeline products for passive prophylaxis in infants, benchmarked against Synagis and Beyfortus

Figure 25: Competitive assessment of pipeline maternal vaccine products, benchmarked against Abrysvo

Figure 26: Competitive assessment of pipeline vaccines for adults, benchmarked against Arexvy, Abrysvo and mRESVIA

Figure 27: Analysis of the company portfolio gap in RSV prophylaxis during the forecast period

Figure 28: Global (8MM) sales forecast by country for RSV prophylactics in 2020 and 2030

Figure 29: US sales forecast by Product for RSV Prophylactics in 2020 and 2030

Figure 30: 5EU sales forecast by product for RSV prophylactics in 2020 and 2030

Figure 31: Japan sales forecast by product for RSV prophylactics in 2020 and 2030

Figure 32: Australia sales forecast by product for RSV prophylactics in 2020 and 2030

Respiratory Syncytial Virus Prophylaxis in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2030 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports

Pharmaceuticals

New

Human Immunodeficiency Virus (HIV) Major Markets: Disease Management, Epidemiology, Pipeline…

Pharmaceuticals

New

Catalyst Monitor: Q2 2026 Outlook

Pharmaceuticals

New

Emerging Market Outsourcing Report, Q1 2026

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Respiratory Syncytial Virus Prophylaxis in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2030 in real time.

Access a live Respiratory Syncytial Virus Prophylaxis in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Respiratory Syncytial Virus Prophylaxis in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2030

Scope

Key Highlights

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports